Alliance Pharma PLC Changes to interests of a significant shareholder (2919E)
May 05 2017 - 2:01AM
UK Regulatory
TIDMAPH TIDMAV.
RNS Number : 2919E
Alliance Pharma PLC
05 May 2017
For immediate release 5 May 2017
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Changes to interests of a significant shareholder
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical
company, has received a notification of a change in the interests
of a significant shareholder. In accordance with AIM rule 17, the
following details are now notified:
(a) Identity of the significant shareholder: Aviva plc and its
subsidiaries
(b) Date of disclosure: 4 May 2017
(c) Date of relevant change: 3 May 2017
(d) Price, amount and class: 4,654,020 ordinary shares of 1p
each; price not disclosed
(e) Nature of transaction: sale of shares
(f) Nature and extent of significant shareholder's interest: direct and indirect interests
(g) Resultant shareholding: 3.86% (direct) and 0.01% (indirect)
= 3.87% total
In compliance with DTR5, a copy of the notification received
from this investor is appended.
For further information:
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Andrew Franklin, Chief Financial
Officer
Rob Bellhouse, Company Secretary
www.alliancepharma.co.uk
+ 44 (0) 20 7466
Buchanan 5000
Mark Court / Sophie Cowles
/ Jane Glover
+ 44 (0) 20 7260
Numis Securities Limited 1000
Nominated Adviser: Michael
Meade / Freddie Barnfield
Corporate Broking: James
Black / Toby Adcock
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international speciality
pharmaceutical company based in Chippenham, Wiltshire, UK. The
Company has sales in more than 100 countries worldwide via direct
sales, joint ventures and a network of distributors. Alliance has a
strong track record of acquiring the rights to established niche
products and it currently owns or licenses the rights to
approximately 90 pharmaceutical and consumer healthcare products.
The Company continues to explore opportunities to expand its
product portfolio.
Alliance joined the AIM market of the London Stock Exchange in
December 2003 and trades under the symbol APH.
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
--------------------------------------------------------------------------------------------------------
1. Identity of the issuer or Alliance Pharma plc
the underlying issuer
of existing shares to which
voting rights are
attached:
--------------------------------------------------------------- ---------------------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
--------------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights
------------------------------------------------------------------- -----------------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
------------------------------------------------------------------- -----------------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
------------------------------------------------------------------- -----------------------------------
An event changing the breakdown of voting rights
------------------------------------------------------------------- -----------------------------------
Other (please
specify):
----------------------------------------------------------- ------ -----------------------------------
3. Full name of person(s) Aviva plc & its subsidiaries
subject to the
notification obligation:
------------------------------------------------------------- -----------------------------------------
4. Full name of shareholder(s) Registered Holder:
(if different from 3.): Available on request 18,450*
Chase (GA Group) Nominees
Limited 18,236,806*
*denotes direct interest
------------------------------------------------------------- -----------------------------------------
5. Date of the transaction 03 May 2017
and date on
which the threshold is
crossed or
reached:
------------------------------------------------------------- -----------------------------------------
6. Date on which issuer 04 May 2017
notified:
------------------------------------------------------------- -----------------------------------------
7. Threshold(s) that is/are 4% to 3% Change at Direct
crossed or Interest Level
reached: (Box 8A & Box 8A&B)
------------------------------------------------------------- -----------------------------------------
8. Notified details:
--------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares
--------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if possible
using
the ISIN
CODE
-------------- --------------------------- -----------------------------------------------------------------
Number Number Number Number of voting % of voting
of of of shares rights rights
Shares Voting
Rights
-------------- ------------- ------------ ----------- --------------------------- -----------------------
Direct Direct Indirect Direct Indirect
-------------- ------------- ------------ ----------- ----------- -------------- ------- --------------
Ordinary
Shares
Not Not
GB0031030819 22,959,276* 22,959,276* 18,255,256 18,255,256 Disclosable** 3.86% Disclosable**
------------- ------------ ----------- ----------- -------------- ------- --------------
* Includes Right to Recall Loaned Shares (50,000)
--------------------------------------------------------------------------------------------------------------
B: Qualifying Financial Instruments
--------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
--------------------------------------------------------------------------------------------------------------
Type of Expiration Exercise/ Number of voting % of voting
financial date Conversion rights that rights
instrument Period may be
acquired if
the
instrument
is
exercised/
converted.
-------------- ------------- ------------------------- --------------------------- -----------------------
RIGHT TO
RECALL 50,000*
LOANED
SHARES N/A N/A *Direct Interest 0.01%
-------------- ------------- ------------------------- --------------------------- -----------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments
-----------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
-----------------------------------------------------------------------------------------------
Type of financial Exercise Expiration Exercise/ Number of voting % of voting
instrument price date Conversion rights instrument rights
period refers to
------------------ --------- ----------- ------------ ------------------- ----------------
Nominal Delta
------------------ --------- ----------- ------------ ------------------- -------- ------
Total (A+B+C)
------------------------------------------------------
Number of voting rights Percentage of voting rights
------------------------ ----------------------------
18,305,256 3.87%
------------------------ ----------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
--------------------------------------------------------------------------------------------
The voting rights are managed and controlled by Aviva
Investors Global Services Limited and Friends Provident
International Limited, with the following chain of controlled
undertakings:-
Aviva Investors Global Services Limited:
* Aviva plc (Parent Company)
* Aviva Group Holdings Limited (wholly owned subsidiary
of Aviva plc)
* Aviva Investors Holdings Limited (wholly owned
subsidiary of Aviva Group Holdings Limited)
* Aviva Investors Global Services Limited (wholly owned
subsidiary of Aviva Investors Holdings Limited)
Friends Provident International Limited:
* Aviva plc (Parent Company)
* Aviva Group Holdings Limited (wholly owned subsidiary
of Aviva plc)
* Friends Provident International Limited (wholly owned
subsidiary of Aviva Group Holdings Limited)
Proxy Voting:
--------------------------------------------------------------------------------------------
10. Name of the proxy holder: See Section 4
-------------------------------------------------- ----------------------------------------
11. Number of voting rights proxy
holder will cease
to hold:
-------------------------------------------------- ----------------------------------------
12. Date on which proxy holder will
cease to hold
voting rights:
-------------------------------------------------- ----------------------------------------
13. Additional information: Figures are based on a total
number of voting rights of
472,795,052, as per the Company's
'Application for admission'
announcement of 31 March 2017.
** - Although not reportable,
as per DTR5.1.5,the non-disclosable
(indirect) position is currently
604,020 shares, and is included
here in the interests of transparency.
-------------------------------------------------- ----------------------------------------
14. Contact name: Neil Whittaker, Aviva plc
-------------------------------------------------- ----------------------------------------
15. Contact telephone number: 01603 684420
-------------------------------------------------- ----------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUGURPAUPMUAA
(END) Dow Jones Newswires
May 05, 2017 02:01 ET (06:01 GMT)
Aviva (LSE:AV.)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aviva (LSE:AV.)
Historical Stock Chart
From Apr 2023 to Apr 2024
